Skip to content

Prospective Collection of Outcome Data Post POEM-TIF Procedure

Assessment of Safety and Outcomes in Patients Undergoing a Standard-of-care Combined POEM-TIF Procedure

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04052581
Enrollment
0
Registered
2019-08-12
Start date
2023-07-31
Completion date
2023-07-26
Last updated
2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achalasia, Gastroesophageal Reflux Disease

Keywords

Per oral Endoscopic Myotomy, Transoral Incisionless Fundoplication, POEM, TIF

Brief summary

Per Oral Endoscopic Myotomy has been established as a safe and effective treatment of Achalasia type I and II; however, it is limited by post-procedure gastroesophageal reflux. Transoral Incisionless Fundoplication (TIF) has been introduced as the endoscopic gold standard for anti-reflux procedure. Recently, combined POEM-TIF has been performed successfully as a standard of care treatment for patients with severe GER after POEM. We aim to study the safety and feasibility of performing POEM-TIF (POEM and TIF in the same endoscopic session). This study will also put the groundwork for a randomized clinical trial to further study the clinical outcome of the POEM-TIF procedure.

Interventions

PROCEDUREPOEM-TIF

Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session

Sponsors

Northwell Health
CollaboratorOTHER
Johns Hopkins University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient age greater than 18 years old * Manometrically proven diagnosis of either type I or type II achalasia.

Exclusion criteria

* Achalasia type III, or other esophageal dysmotility disorders. * Completion of POEM with evidence of mucosal injury or compromise * Previous surgery of the stomach such as sleeve gastrectomy, gastric bypass, Heller myotomy, partial or complete fundoplication, or partial/complete gastrectomy * Esophageal lumen diameter greater than 4 cm * Sigmoidization of the esophagus * Large esophageal diverticula * Known active gastroesophageal malignancy * Inability to tolerate sedated upper endoscopy due to cardiopulmonary instability, severe pulmonary disease or other contraindication to endoscopy * Cirrhosis with portal hypertension, varices, and/or ascites * Pregnant or breastfeeding women (all women of child-bearing age will undergo urine pregnancy testing) * Acute gastrointestinal bleeding * Uncorrectable coagulopathy defined by international normalized ratio (INR) \> 1.5 or platelet \< 50,000

Design outcomes

Primary

MeasureTime frameDescription
Safety of POEM-TIF as assessed by the American Society of Gastrointestinal Endoscopy (ASGE) lexicon scoring system6 monthsSafety will be evaluated by the frequency of severe adverse events with probable or definite attribution to the procedure based the ASGE lexicon scoring system. ASGE lexicon's severity grading system classify the adverse events into one of the four categories of mild, moderate, severe, and fatal. Mild adverse event means an adverse event that result in (1) Procedure aborted (or not started) because of an adverse event, (2) Post-procedure medical consultation, or (3) Unplanned hospital admission or prolongation of hospital stay for lesser or equal to 3 nights. Fatal grade adverse event happens when the procedure cause death.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026